CY1112600T1 - Φαρμακευτικη συνθεση περιεχουσα 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικο κινουκλιδιν-3'-υλιο για την αγωγη της διαμεσης κυστιτιδας και/ή της μη βακτηριακης προστατιτιδας - Google Patents

Φαρμακευτικη συνθεση περιεχουσα 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικο κινουκλιδιν-3'-υλιο για την αγωγη της διαμεσης κυστιτιδας και/ή της μη βακτηριακης προστατιτιδας

Info

Publication number
CY1112600T1
CY1112600T1 CY20111100272T CY111100272T CY1112600T1 CY 1112600 T1 CY1112600 T1 CY 1112600T1 CY 20111100272 T CY20111100272 T CY 20111100272T CY 111100272 T CY111100272 T CY 111100272T CY 1112600 T1 CY1112600 T1 CY 1112600T1
Authority
CY
Cyprus
Prior art keywords
tetrahydroisoquinoline
capsaicin
cinoclidin
fenyl
purchase
Prior art date
Application number
CY20111100272T
Other languages
English (en)
Inventor
Ken Ikeda
M Takeuchi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1112600T1 publication Critical patent/CY1112600T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ένα κατασταλτικό των ευαίσθητων στην καψαϊκίνη αισθητήριων νεύρων, περιέχον 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικό κινουκλιδιν-3'-ύλιο ή ένα άλας του ως δραστικό συστατικό, συγκεκριμένα ένα θεραπευτικό φάρμακο για τη διάμεση κυστίτιδα, τη διαταραχή υπερευαισθησίας της κατώτερης ουροποιητικής οδού και/ή τη μη βακτηριακή προστατίτιδα.
CY20111100272T 2001-07-10 2011-03-11 Φαρμακευτικη συνθεση περιεχουσα 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικο κινουκλιδιν-3'-υλιο για την αγωγη της διαμεσης κυστιτιδας και/ή της μη βακτηριακης προστατιτιδας CY1112600T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001209041 2001-07-10
EP02741446A EP1405638B1 (en) 2001-07-10 2002-07-08 Pharmaceutical composition comprising quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate for treatment of interstitial cystitis and/or abacterial prostatitis

Publications (1)

Publication Number Publication Date
CY1112600T1 true CY1112600T1 (el) 2016-02-10

Family

ID=19044753

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100272T CY1112600T1 (el) 2001-07-10 2011-03-11 Φαρμακευτικη συνθεση περιεχουσα 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικο κινουκλιδιν-3'-υλιο για την αγωγη της διαμεσης κυστιτιδας και/ή της μη βακτηριακης προστατιτιδας

Country Status (19)

Country Link
US (2) US7335668B2 (el)
EP (1) EP1405638B1 (el)
JP (1) JP4174673B2 (el)
KR (1) KR100874815B1 (el)
CN (1) CN1270708C (el)
AT (1) ATE497765T1 (el)
AU (1) AU2002315814B2 (el)
BR (1) BR0210873A (el)
CA (1) CA2449922C (el)
CY (1) CY1112600T1 (el)
DE (1) DE60239134D1 (el)
DK (1) DK1405638T3 (el)
ES (1) ES2359719T3 (el)
MX (1) MXPA04000124A (el)
PL (1) PL208138B1 (el)
PT (1) PT1405638E (el)
RU (1) RU2290929C2 (el)
WO (1) WO2003006019A1 (el)
ZA (1) ZA200309632B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558877A1 (en) * 2004-02-09 2005-08-18 Astellas Pharma Inc. Solifenacin succinate-containing composition
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
US7820690B2 (en) * 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
US8039482B2 (en) 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
CN101601673B (zh) * 2004-03-25 2012-07-18 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
EP1775283A4 (en) * 2004-07-14 2008-12-10 Japan Tobacco Inc 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
BRPI0513286A (pt) 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
EP1832288B1 (en) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
US20090131469A1 (en) * 2005-02-25 2009-05-21 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
JP4614084B2 (ja) * 2005-07-25 2011-01-19 アステラス製薬株式会社 キヌクリジン誘導体含有医薬組成物
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CA2632508A1 (en) 2005-12-28 2008-06-05 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity
TWI482629B (zh) * 2008-07-01 2015-05-01 Tobishi Pharmaceutical Co 下泌尿道疾病治療劑及下泌尿道症狀改善劑
MD4025C2 (ro) * 2009-08-25 2010-10-31 Владимир КАРАУШ Remediu pentru tratamentul prostatitei şi hiperplaziei prostatei
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
PT1011695E (pt) * 1997-07-15 2006-07-31 Univ Colorado Utilizacao de terapia com neurotoxina para tratamento de doencas da prostata
KR100375003B1 (ko) * 1998-11-05 2003-03-06 다이호야쿠힌고교 가부시키가이샤 배뇨장애 치료제
AU6686700A (en) * 1999-08-23 2001-03-19 H. Lundbeck A/S Treatment of urinary incontinence

Also Published As

Publication number Publication date
US20090105298A1 (en) 2009-04-23
PL366731A1 (en) 2005-02-07
US7335668B2 (en) 2008-02-26
ATE497765T1 (de) 2011-02-15
EP1405638A4 (en) 2006-04-12
EP1405638A1 (en) 2004-04-07
RU2290929C2 (ru) 2007-01-10
BR0210873A (pt) 2004-06-22
US20040138252A1 (en) 2004-07-15
MXPA04000124A (es) 2004-05-21
ES2359719T3 (es) 2011-05-26
PL208138B1 (pl) 2011-03-31
KR100874815B1 (ko) 2008-12-19
DE60239134D1 (de) 2011-03-24
KR20040029358A (ko) 2004-04-06
RU2004103746A (ru) 2005-03-27
CN1270708C (zh) 2006-08-23
CA2449922C (en) 2008-11-25
CN1527708A (zh) 2004-09-08
PT1405638E (pt) 2011-04-06
EP1405638B1 (en) 2011-02-09
WO2003006019A1 (fr) 2003-01-23
AU2002315814B2 (en) 2007-05-31
JPWO2003006019A1 (ja) 2004-10-28
ZA200309632B (en) 2004-12-22
CA2449922A1 (en) 2003-01-23
DK1405638T3 (da) 2011-04-18
JP4174673B2 (ja) 2008-11-05

Similar Documents

Publication Publication Date Title
CY1112600T1 (el) Φαρμακευτικη συνθεση περιεχουσα 1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικο κινουκλιδιν-3'-υλιο για την αγωγη της διαμεσης κυστιτιδας και/ή της μη βακτηριακης προστατιτιδας
GB0225474D0 (en) Therapeutic agents
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CY2014031I2 (el) Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae
WO2003083067A3 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
PL374865A1 (en) Treatment of tnf alpha related disorders
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
DE69618231T2 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
ATE412749T1 (de) Chemisch modifizierter gewebeinhibitor für metalloproteasen type 3 (timp-3)
GB0318447D0 (en) Therapeutic agents
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
DE69512930D1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
GB0223038D0 (en) Therapeutic compounds
DE60112974D1 (en) Carbolinderivate
HK1060729A1 (en) Inhibitors of cruzipain and other cysteine proteases
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA02012659A (es) Derivados de pirazindiona condensados.
DK1407784T3 (da) Antitumormidler
NO942466D0 (no) Kontrast Media
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
WO2004030671A3 (en) Use of 4-amino-quinazolines as anti cancer agents
GB0522908D0 (en) Therapeutic agents